Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up

Table 2 Frequency distribution of PAM50 intrinsic subtypes and risk of recurrence score

	All patients		Node-negative patients^a		Node-positive patients^a
	No. of patients	%	No. of patients	%	No. of patients	%
All patients	653	100	419	64.2	218	33.4
PAM50 intrinsic subtype
Luminal A	341	52.2	240	57.3	95	43.6
Luminal B	173	26.5	103	24.6	65	29.8
HER2enriched	69	10.6	30	7.2	38	17.4
Basal-like	70	10.7	46	11.0	20	9.2
ROR score, median	51		46		56
HR+/HER2− patients	476	100	318	66.8	149	31.3
ROR risk score classification
Low risk	180	37.8	145	45.6	33	22.1
Intermediate risk	108	22.7	104	32.7	–	–
High risk	188	39.5	69	21.7	116	77.9
ROR score, median	46		42		50

Abbreviations: HER2 Human epidermal growth factor receptor 2, HR Hormone receptor, ROR Risk of recurrence
^aNine patients were classified as pNX

ISSN: 1465-542X